Hematide entered into phase 3 clinical program to treat anemia in chronic renal failure patients in Japan
Hematide™, a synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is designed to act on the erythropoietin receptors and stimulate the production of red blood cells by dosing once every four weeks.
Takeda and Affymax have been conducting phase 3 program in the US and EU. Follow-up of patients in the phase 3 program was completed in January 2010 and top-line study results are expected to be reported in the 1Q of FY 2010. An NDA submission in the U.S. is expected later in 2010.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.